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progress and its applications, and a right to the protection 
of the moral and material interests resulting from scientific 
productions. It is time to apply these twin rights to inter-
nationally collaborative genomic and clinical data sharing.
Introduction
In 1948, the General assembly of the United nations 
adopted the Universal Declaration of Human Rights 
(UDHr) to guarantee the rights of every individual in the 
world. Included were twin rights “to share in scientific 
advancement and its benefits” and “to the protection of 
the moral and material interests resulting from any scien-
tific…production of which [a person] is the author” (art. 
27, United nations 1948). In the 21st century, where are 
we in realizing the sharing of scientific advancement and 
its benefits, and the importance of protecting a scientific 
producer’s moral and material interests? In this article, we 
argue that these little-developed twin rights, what we call 
the right “to benefit from” and “to be recognized for”, have 
direct application to internationally collaborative genomic 
and clinical data sharing, and can be activated through an 
international code of conduct.
sharing genomic and clinical data is critical to achieve 
precision medicine (national research Council 2011), that 
is, more accurate disease classification based on molecular 
profiles to enable tailored effective treatments, interven-
tions, and models for prevention. Better communication 
flow across borders and research teams, encompassing data 
from clinical and population research, enables research-
ers to connect the diverse types of datasets and expertise 
needed to elucidate the genomic basis and complexities of 
disease etiology. such data integration can make it possi-
ble to reveal the genetic basis of cancer, inherited diseases, 
Abstract Fostering data sharing is a scientific and ethi-
cal imperative. Health gains can be achieved more compre-
hensively and quickly by combining large, information-rich 
datasets from across conventionally siloed disciplines and 
geographic areas. While collaboration for data sharing is 
increasingly embraced by policymakers and the interna-
tional biomedical community, we lack a common ethical 
and legal framework to connect regulators, funders, con-
sortia, and research projects so as to facilitate genomic 
and clinical data linkage, global science collaboration, and 
responsible research conduct. Governance tools can be used 
to responsibly steer the sharing of data for proper steward-
ship of research discovery, genomics research resources, 
and their clinical applications. In this article, we propose 
that an international code of conduct be designed to ena-
ble global genomic and clinical data sharing for biomedi-
cal research. to give this proposed code universal applica-
tion and accountability, however, we propose to position it 
within a human rights framework. this proposition is not 
without precedent: international treaties have long recog-
nized that everyone has a right to the benefits of scientific 
B. M. Knoppers (*) · e. s. Dove 
Centre of Genomics and Policy, McGill University, 740 Dr. 
Penfield avenue, suite 5200, Montreal H3a 0G1, Canada
e-mail: bartha.knoppers@mcgill.ca
e. s. Dove 
e-mail: edward.dove@mcgill.ca
J. r. Harris · I. Budin-ljøsne 
Division of epidemiology, Department of Genes 
and environment, norwegian Institute of Public Health,  




896 Hum Genet (2014) 133:895–903
1 3
infectious diseases, and drug responses. Indeed, “[b]y 
aggregating and analyzing large amounts of genomic and 
clinical data, it should be possible to discover patterns that 
would otherwise remain obscure—for example, which 
mutations within a tumor predict treatment response, or 
which genetic variants explain rare childhood diseases” 
(Global alliance 2013a). Furthermore, integrating genomic 
data with medical or health records systems securely stored 
in research and clinical databases, as the eMerGe net-
work (http://emerge.mc.vanderbilt.edu/) is beginning to do, 
can help clinicians develop earlier and more targeted treat-
ment strategies for their patients.
the culture of sharing and the development of policies 
to enable research collaboration are clearly pervasive in 
genomics research (Budin-ljøsne et al. 2014; Dyke and 
Hubbard 2011; Knoppers et al. 2011a) and were propelled 
by the groundbreaking human genome project (HGP) data 
release policy, known as the “Bermuda Principles” [Human 
Genome Organisation (HUGO) 1996]. Data sharing is now 
emerging in clinical research as well (Mello et al. 2013; 
vickers 2006). It is not only driven by numerous interna-
tional research initiatives (examples can be found in table 1 
of Harris et al. 2012), but also encouraged by many patients 
and patient organizations, physicians, pharmacists, regula-
tors, and pharmaceutical companies which view data shar-
ing as critical to accelerating research and improving health 
(http://www.alltrials.net/; http://www.free-the-data.org/; 
http://www.patientslikeme.com/; http://www.personalgeno
mes.org/; https://www.reg4all.org/; Kaye et al. 2012; terry 
and terry 2011). In addition, infrastructural initiatives such 
as P3G’s International Policy interoperability and data 
access Clearinghouse (IPaC) (http://www.p3g.org/ipac) 
work at building internationally interoperable tools for data 
access and sharing. However, while data sharing and collab-
oration are increasingly embraced by policymakers, patient 
advocacy groups and the international biomedical research 
community, inefficiencies and insufficiencies remain.
Obstacles to successful global genomic and clinical data 
sharing
Current data sharing models and policies are not working. 
the time lags between discovery and translation remain 
too long, in part the result of ongoing inadequate multi-
disciplinary collaboration (Contopoulos-Ioannidis et al. 
2008). Data are often analyzed in isolated disciplinary or 
institutional silos and with incompatible methods. regu-
latory systems were not designed (nor updated) to fos-
ter widespread cross-study collaboration and transborder 
open sharing of data. “even where local consent or ethics 
approval allows data sharing, providing data to researchers 
in other institutions and countries often requires additional 
approvals (even when the foreign researchers intend to use 
the data in a protocol approved by their own local ethics 
committee)” (Global alliance 2013a). relatedly and sig-
nificantly, there is an absence of universal and enforceable 
guiding norms that can facilitate an internationally collabo-
rative “harmonizing global science” (leshner and turekian 
2009) and responsible research conduct. In addition to the 
problems above, four key obstacles are worth highlighting.
lack of policy harmonization
Data sharing is hindered by the lack of harmonization 
between the policies and procedures of research initiatives 
(austin et al. 2012) and of funders. For example, some 
consortia require a data sharing plan (H3africa 2013) 
and data deposit in a public research database [H3africa 
2013; International Cancer Genome Consortium (ICGC) 
2012; International rare Diseases research Consortium 
(IrDirC) 2013], but others do not make such require-
ments. a further complicating factor is that these data 
sharing procedures often only apply for the duration of the 
funded research project, leaving the fate of the data unclear 
after the collaboration ends (Budin-ljøsne et al. 2014). 
lack of harmonization between biobank practices can 
also create barriers to data sharing. examples include spe-
cial agreements which create limits to data sharing when 
the policies restrict data release to preferred local research 
groups (Fortin et al. 2011).
lack of structural support
the financial, organizational, technical, and governance 
structures to support data sharing vary considerably between 
data sources. While some large community resources bene-
fit from sufficient financial support and solid infrastructures 
to share data, such as the International HapMap Project 
(http://hapmap.ncbi.nlm.nih.gov/abouthapmap.html) and the 
1000 Genomes Project (http://www.1000genomes.org/), 
other research projects, while required to share data, have 
less resources available to do so on a sustainable basis and 
often lack the administrative and legal support to make the 
data available (Budin-ljøsne et al. 2014).
legal and ethical hurdles
even when sufficient resources are in place to share data, 
legal and ethical hurdles may render data sharing difficult 
or even impossible (Kuner 2013; Zink and silman 2008). 
For instance, the informed consent of the original study 
may restrict data sharing, or the research ethics commit-
tee of the original study may be reluctant to approve data 
sharing because of privacy and confidentiality concerns 
(McGuire et al. 2011; Peppercorn et al. 2012).
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Cultural and behavioral considerations
In certain instances, global data sharing could be ethically 
and legally possible, yet may still be hindered by cultural 
and behavioral considerations. For instance, research 
groups in low-income countries may worry that the results 
derived from data sharing, and the ability to use data and 
gain normal scientific rewards and recognition, may not be 
equitably shared with the communities that have contrib-
uted data (H3africa 2013). as a result, researchers may be 
reluctant to share data they have spent years of effort to col-
lect (Pearce and smith 2011). the general lack of incen-
tives to share data in a highly competitive environment and 
the lack of tradition for sharing data outside of one’s own 
professional discipline can further impede data sharing 
(Budin-ljøsne et al. 2014).
to overcome these obstacles, a number of innova-
tive solutions and tools have been proposed. they aim to 
facilitate the recognition of research contributions, help 
motivate researchers and the administrators of biobanks 
to develop and endorse solid data sharing plans, and train 
junior researchers on responsible data sharing and reuse 
practices (Harris et al. 2012; Pan et al. 2012). However, 
these solutions are primarily developed and used only 
within a few well-connected groups and are not univer-
sally applied. these solutions also tend not to be robust 
enough to adequately address issues related to data sharing 
that matter to participant-patients and researchers, namely 
privacy, anti-discrimination and fair access, and propor-
tionate regulatory treatment of research projects. Further-
more, practical tools alone are insufficient to realize the 
ideal of widespread, international, and cross-disciplinary 
data sharing.
so how can we work toward a translational, transna-
tional genome science that is cognizant of the need to 
incentivize data producers to share, to afford researchers 
proportionate regulatory treatment of research projects, 
and to address possible patient-participant concerns about 
the impact of data sharing on privacy, anti-discrimination, 
and fair access? a new framework is needed that symbol-
izes both the emerging relationship among 21st century 
data-intensive science, publics, governments, and research 
funders, and also the embedding of science in social and 
political life (Dandara et al. 2012). a human rights frame-
work can offer this.
What can human rights offer translational 
and transnational genome science?
Human rights are engrained in international law. they offer 
many advantages to translational and transnational genome 
science centered on data sharing, and can better address 
the data sharing obstacles identified in the previous sec-
tion. Indeed, their universalizing force can overcome site-
specific factors that drive a wedge between research initia-
tive/funder data sharing policies and harmonization. First, 
because human rights have both political and legal dimen-
sions, they reach beyond the moral appeals of bioethics and 
can provide a more robust governance framework for the 
regulation of genomics research (Knoppers 2004). Because 
they carry international legal force, they can better promote 
and delineate the contours of responsible access, sharing, 
and attribution of both research and clinical data. Indeed, 
if health care becomes a primary location for collecting the 
phenotypic and genetic data needed to create learning sys-
tems for research and clinical care, we need to reinforce the 
self-regulatory codes of ethics of genomic researchers and 
clinicians with legally recognized human rights, that is, a 
co-regulatory system.
second, human rights belong to groups as well as indi-
viduals (spurring a reciprocity between the individual and 
public level) and reach beyond classic negative duties (i.e. 
forbidding state actors from interfering with the rights of 
individuals, such as the freedom of expression or the right 
to privacy) to positive, more progressive duties, urging 
action by governments (and ideally, industry, funders, and 
researchers) to share the data, technologies and knowledge 
that are the fruits of our science to achieve a goal desired 
by all, such as health (Meslin and Garba 2011).
another advantage is that human rights can foster 
responsible translational genomic research by offering 
stronger protection in three critical areas: privacy; anti-dis-
crimination and fair access; and procedural fairness.
Privacy
there is concern that sharing certain types of data, particu-
larly identifiable or coded (reversibly de-identified) pheno-
typic data (which often happens to be clinical data), raises 
serious privacy problems. Data sharing is not in opposi-
tion to privacy and should be conducted in a responsible 
way such that it does not infringe on the privacy rights 
of individuals and groups. We believe privacy concerns 
can be attenuated by human rights protections and robust 
safeguards built within a principled proportionate govern-
ance model (sethi and laurie 2013) and a code of conduct 
that recommends sharing sensitive data within strict limits 
that respect both laws and ethical guidelines (i.e. sharing 
data only with “prescribed entities” or within data “safe 
havens”). as we have argued elsewhere, “despite the per-
ceived ease of re-identification, … technologies and models 
currently exist that facilitate dissemination of useful health 
data without compromising privacy” (Knoppers et al. 
2012). self-regulatory instruments and proportionate gov-
ernance mechanisms like codes of conduct can be human 
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rights attuned and offer privacy protection. In fact, they are 
supported by the proposed european general data protec-
tion regulation, which encourages associations (including 
funders and research consortia) to draw up codes of con-
duct that protect the personal data of individuals and confer 
enforceable rights on them (art. 38, european Commission 
2012; european Parliament 2013).
Further, human rights better protect privacy than status 
quo informed consent arrangements or bioethical norms 
alone, for they can (1) hold data users legally account-
able, (2) promote feasible, ethically robust standards 
of data governance, and (3) treat privacy and scientific 
advancement and its benefits as human rights (not mere 
interests) to promote, respect, fulfill, and balance. While 
maintaining individual choice models such as informed 
consent, individual and group privacy concerns, at least 
those shared by most if not all people, should be assuaged 
through strong privacy and data security protections 
beyond informed consent.
Without question, however, the sensitive nature of clini-
cal data remains a challenge, and if we want to achieve a 
globally collaborative science that harnesses genomic 
and clinical data sharing, we must strike a careful bal-
ance between protecting personal health data from misuse 
and sharing these data to accelerate health improvements. 
nowhere is this more critical than in the genomics context: 
“at present, it is generally not possible to predict which 
changes in Dna sequence lead to clinical consequences. 
Only by comparing each personal genome sequence to a 
large repository of other such data can robust patterns and 
relationships be identified. the stakes are high, because if 
we get it right we can create new opportunities to define 
diagnostic categories, streamline clinical trials, and match 
patients to therapy. We want to make sure this is done in 
a global manner, and with the highest standards for ethics 
and privacy” (Global alliance 2013b).
anti-discrimination and fair access
Concerns of genetic discrimination or discrimination 
based on health information are widespread (Otlowski 
et al. 2012), as are concerns about fair or equitable access 
to data, research results, and public health benefits derived 
from those results (de vries et al. 2011; H3africa 2013). 
anti-discrimination and equitable treatment are also central 
principles of international human rights law. as article 2 of 
the Un’s 1966 International Covenant on economic, social 
and Cultural rights (ICesCr) obliges states to guaran-
tee that the rights enunciated in the Covenant are exer-
cised without discrimination of any kind, including status, 
human rights instruments must allow for meaningful sanc-
tions for those who misuse personal data (Joly et al. 2011), 
including genome sequences that have been volunteered for 
the public good, for unethical or unlawful purposes, be it 
discrimination, group stigmatization, misrepresentation, or 
other negative uses (editorial 2013). Human rights promote 
capacity building, which include the sharing of data, knowl-
edge, and resources in currently underserved regions. this 
can help research projects overcome the persistent obstacle 
of weak structural support for data sharing, as well as cul-
tural or community concerns that data, scientific rewards, 
and recognition may not be equitably shared with the com-
munities that have contributed data. as with privacy, treat-
ing fair access, anti-discrimination, and harm protection as 
fundamental principles allows data sharing to be seen as 
a scientific and ethical imperative (Ohno-Machado 2012) 
that must always be balanced against competing principles 
or rights, and not as an unconditional legal duty imposed 
on any person or entity.
Procedural fairness
legal and ethical hurdles in data sharing are often the 
results of disproportionate research oversight. as a matter 
of natural justice, and as protected in human rights instru-
ments, there must be fairness in procedures related to reg-
ulatory treatment of research projects. In particular, there 
must be a proportional approach in law or policy guidelines 
to clearly distinguish between degrees of risk (Dove et al. 
2013). Genomic studies or uses of clinical data or samples 
that involve only non-physical, informational risks should 
be treated differently (that is, less onerously) than clinical 
trials with direct physical interventions on the human body. 
this new informational “de minimis” risk category (rho-
des et al. 2011) is suggested for “research that uses genetic 
information or existing (i.e. stored) biospecimens and [for] 
research that uses information from databases, medical reg-
istries, patient records, and questionnaires or interviews 
with competent, adult research participants” (Hansson et al. 
2013). such an informational category of “de minimis risk” 
genomic research and medicine would require that personal 
information be safeguarded from use by those not directly 
associated with biomedical research and clinical medicine, 
particularly criminal investigators, insurers, and employers. 
Furthermore, human rights would necessitate that prospec-
tive contributors, users, and authors who are directly asso-
ciated with the domain abide by ethical access conditions.
A code of conduct to bridge solidarity human rights 
to our “social genome”
While the types of human rights invoked in research gov-
ernance policies vary, often policies have focused on pro-
tecting against individual exploitation and harm, rather 
than on promoting social and economic development that 
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situates genomics research and applications as a public 
good that enhances human capabilities and economic pro-
ductivity (ashcroft 2007). Yet, there is an underlying com-
plementarity between genome science and human rights, 
especially with social goods-focused human rights and 
“solidarity rights” that include, for instance, the recogni-
tion of the human genome (at the level of the species) as 
the common heritage of mankind (Knoppers 1991; Kup-
puswamy 2009).
solidarity rights are longstanding in international 
law. In addition to the 1948 UDHr, the 1966 ICesCr 
enshrined at art. 15(1)(b) the right “of everyone … to 
enjoy the benefits of scientific progress and its applica-
tions” and the right “of everyone …to benefit from the 
protection of the moral and material interests result-
ing from any scientific … production of which he is 
the author” [art. 15(1)(c)]. Importantly, the ICesCr is 
legally binding on nations that are states Parties (unlike 
the 1948 Universal Declaration). they have a duty to 
respect, protect and fulfill the rights articulated in the 
ICesCr (Donders 2011). this means that all 160 mem-
ber nations must promote “the development and the dif-
fusion of science” [art. 15(2)] and “recognize the benefits 
to be derived from the encouragement and development 
of international contacts and cooperation in the scien-
tific…field” [art. 15(4)] (United nations 1966). Moreo-
ver, in 2013, an optional protocol entered into force that 
establishes a complaint mechanism at the international 
level for people whose rights in the ICesCr have been 
violated and who have not obtained justice in their own 
country (United nations 2008).
these twin rights “to benefit from” and “to be rec-
ognized for” are neither self-evident nor promoted in the 
world of genomics. Indeed, they remain extremely under-
developed as a whole (Chapman 2009; Donders 2011) 
and have been cited in only a handful of court decisions 
around the world, and each time only in passing reference. 
Yet, from our perspective, the right “to benefit from”, i.e. 
to enjoy the benefits of scientific progress and its applica-
tions, clearly implies a right that all can exercise to have 
access to and share in both the development and fruits 
of science across the translation continuum, from basic 
research through practical, material application (e.g. diag-
nostics and therapeutics). the right is directly linked to 
other human rights, especially the right to health, but also 
to information, expression, association, privacy, and anti-
discrimination. as a recent Un report notes, “the ‘ben-
efits’ of science encompass not only scientific results and 
outcomes but also the scientific process, its methodologies 
and tools” (shaheed 2012). and as an international consen-
sus statement from 2009 notes, “this right can be enjoyed 
individually and collectively” and “implies…scientific 
freedom, including freedoms of opinion and expression, 
to seek, receive and impart information, association and 
movement” (UnesCO 2009). In genomics research, it is a 
right that all who stand to benefit from genomics can exer-
cise. this right includes opportunities for citizens to take 
the initiative to share their personal data with the research 
community (http://www.free-the-data.org/).
similarly, the right “to be recognized for”, i.e. to ben-
efit from the protection of the moral and material inter-
ests resulting from scientific productions, means that 
all individuals who author or create scientific produc-
tions should be acknowledged, and should have their 
productions valorized if they so choose. It also means 
they should have their production’s integrity respected. 
In genomics research, it is a right that all data produc-
ers or contributors (e.g. stewards of data repositories) can 
exercise in the course of data sharing. the right suggests 
the need for recognition of attribution for data producers 
and contributors, and perhaps also intellectual property 
rights. However, as recognized by the Un committee on 
economic, social and cultural rights, intellectual property 
rights (such as copyright and patent) must be balanced 
with the right to enjoy the benefits of scientific progress 
and its application: “Ultimately, intellectual property 
is a social product and has a social function. the end 
which intellectual property protection should serve is the 
objective of human well-being, to which international 
human rights instruments give legal expression” (United 
nations, Committee on economic, social and Cultural 
rights 2001).
to apply these twin human rights to translational and 
transnational genome science, we must move beyond sin-
gular policies within funders, research consortia, and bio-
medical clinical ethics to the meta-level of global govern-
ance that works from a universally shared legal, human 
rights framework for addressing international problems. 
Bioethics norms by themselves have created the necessary 
foundations to move to this next step (art. 3 of the Uni-
versal Declaration on Bioethics and Human rights notes 
that, “Human rights…are to be fully respected”) (UnesCO 
2005). However ethical norms alone lack the articulation 
of the force of governmental and other regulatory stake-
holder duties and standards of accountability. a human 
rights perspective can “lay bare the societal importance of 
the issue and can help mobilize civil society and advocacy 
groups. It calls for prioritization of the issue on the public 
policy agenda” (lemmens 2013). thus, we suggest look-
ing at tools available in the genomics research governance 
system, in addition to bioethics norms, that can be used to 
responsibly steer the sharing and stewardship of research 
discovery, genomics research resources, and their integra-
tion with clinical data for genomic medicine.
It is our contention that regulatory and governance 
design to enable global collaboration and realization of the 
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twin rights “to benefit from” and “to be recognized for” 
requires an international code of conduct for genomic and 
clinical data sharing situated within a human rights frame-
work. It would (a) interpret the right to enjoy the benefits 
of scientific progress and its applications as being the right 
to access and share genomic and clinical data across the 
translation continuum, from basic research through practi-
cal, material application (e.g. diagnostics and therapeutics); 
and (b) apply the right to benefit from the protection of the 
moral and material interests resulting from scientific pro-
ductions to genomic research by developing rights such 
as a right of attribution and a right to integrity of the pro-
duction for data producers and contributors. Further, this 
code would establish a set of principles and procedures for 
responsible research conduct, founded on and guided by 
complementary human rights principles such as privacy, 
anti-discrimination, and procedural fairness.
a rights-informed code would be targeted at the struc-
tural level of governance frameworks that impose obsta-
cles to data sharing, not at the level of individuals, whom 
we stress are not obligated to share genomic or clinical 
data. Choice remains primary: “the right to share in sci-
entific benefits should not be predicated on participation” 
(UnesCO 2009). state governments are the principal, but 
certainly not only, entities responsible for the promotion 
and protection of international human rights, and there-
fore should sign onto a code to commit themselves to three 
duties. they must respect these twin rights, i.e. “respect 
the freedom of the scientific community and its individual 
members to collaborate with others both within and across 
the country’s borders, including the free exchange of infor-
mation, research ideas and results” (UnesCO 2009). they 
must protect these twin rights, i.e. pass laws or regulations 
that ensure that private non-state parties do not violate the 
rights, including a right of attribution of data contributors 
or producers. and they must fulfill these twin rights, i.e. 
undertake an obligation to progressively make the rights 
a reality through infrastructural and institutional measures 
that promote data sharing.
the human rights framework, with its universal scope 
and legally enforceable mechanisms adhered to by state 
and non-state actors, can effectively regulate behavior and 
set norms as genomic data are joined with clinical data to 
create international databases for researchers and clini-
cians to access such data. In addition to the protections 
discussed above, this approach would also protect patient-
centric systems of dynamic participation that provide infor-
mation and support resources for the individual contribu-
tion of sensitive data (medical, genetic, etc.) for research 
use around the world (terry et al. 2013). the human rights 
framework would help to achieve the realization of the 
“social genome” (Knoppers and Joly 2007) under inter-
national law, and can provide the appropriate mechanisms 
for ensuring respect of the ethical principles (Chapman 
and Wyndham 2013) that have framed the self-regulatory 
norms of genomics research to date. this contention is 
supported by a Un report, which notes that: “[d]eveloping 
codes of conduct explicitly informed by human rights…
seems essential” (shaheed 2012).
Possible objections to a human rights framework
situating a code of conduct within a human rights framework 
faces some objections. First, some may argue that human 
rights or international codes or declarations can only be, 
at best, an amalgamation of minimalist or vague claims to 
achieve international consensus, or, at worst, merely a cultur-
ally imperialist Western ideological construct (Benatar 2005). 
We think, on the contrary, that all people are entitled to basic 
rights by the mere fact of their human condition. to be human 
is to possess certain fundamental rights, regardless of one’s 
status. let us recall that essentially all of the world’s countries 
have ratified the UDHr, which itself was drafted by members 
composed of varying religious and philosophical and cultural 
traditions, and 160 countries have ratified the ICesCr. the 
fundamental rights contained in the UDHr and ICesCr are 
not imposing one cultural standard. rather, they are setting 
a baseline legal standard that all individuals and peoples can 
invoke to ensure basic human dignity and, quoting the Pre-
amble of the UDHr, to establish the conditions “for freedom, 
justice and peace in the world” (United nations 1948). also, 
rather than being culturally imperialist, human rights entail 
international cooperation: “It is particularly incumbent upon 
those states which are in a position to assist others” to help 
provide access to and use of science and technology (United 
nations, Committee on economic, social and Cultural rights 
1990). responsibly sharing genomic and clinical data around 
the globe is an important component of international coop-
eration and assistance that reflects not a Western ideological 
construct but a belief in human solidarity.
second, some may argue that human rights, and more 
broadly, international law, face accountability, monitoring, 
and enforcement problems. short of binding law, how can 
codes of conduct be governed and enforced effectively? 
While it may be true that individuals or communities can-
not always directly enforce or invoke in a court of law the 
twin rights “to benefit from” and “to be recognized for,” 
these rights exist nonetheless; states are legally bound to 
implement them and non-state parties are bound to respect 
them. One solution alluded to above could be that govern-
ments or regulatory agencies endorse a code of conduct, 
similar to what they do for binding corporate rules (BCrs) 
(Moerel 2012), and what the european Commission aims 
to do in its proposed General Data Protection regulation 
(art. 38, european Commission 2012; european Parlia-
ment 2013). this would put the obligation to monitor and 
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enforce codes on governments, supervisory bodies, and 
non-governmental organizations alike. Moreover, funding 
agencies and even industry could make compliance with 
codes of conduct a special term and condition in notices of 
award or in contracts. Failure to comply with a code could 
lead to enforcement actions such as funding withholds or 
termination, as well as remedies for those individuals or 
groups whose access rights have been infringed or who 
face breaches to privacy, discrimination, or violations of 
procedural fairness.
Conclusion: toward a code of conduct for global 
genomic and clinical data sharing
this article has advocated for a durable, communal, and 
purpose-driven code of conduct set within a human rights 
framework that both realizes and maximizes the sharing of 
scientific progress and its applications for all while provid-
ing proper attribution for scientific producers. We believe 
that in so doing, a code can set an innovative but effective 
and ethically responsible approach to sharing genomic and 
clinical data. It can help move us beyond risk-focused prin-
ciples and policies to a framework that views genomic and 
clinical databases as global public goods (Human Genome 
Organisation (HUGO) 2002) that must be respected, pro-
tected, and promoted, and that draws a roadmap for con-
ducting collaborative genome science in an ethically 
responsible, solidaristic manner. It will also elaborate and 
clarify the normative content of rights and the correspond-
ing obligations of parties. this allows “individuals and 
communities [to] learn what they are legally entitled to, 
states [to] know what kind of legal obligations they have 
in relation to the implementation of these rights and super-
visory bodies [to] monitor the performance of states in this 
regard” (Donders 2011).
Knowledge production is increasingly conducted in 
teams (Wuchty et al. 2007). a global alliance of interna-
tional partners, from research organizations to funders to 
industry and governments, must work together to create 
conditions for the availability, accessibility, and accept-
ability of quality genomic and clinical data that improve 
human health. Global governance “must take root ab initio 
and be co-produced as part of a larger, collaborative, co-
evolving social structure that includes data-intensive sci-
ence, technology, and genomics medicine” (Dandara et al. 
2012). Only by working together to develop common prin-
ciples, as well as more practical policies and procedures, 
can patients, participants, researchers, and clinicians safely 
and effectively share data, protect and promote privacy, and 
foster medical progress across the globe.
therefore, building on a genomic data sharing code of 
conduct we previously proposed (Knoppers et al. 2011b), 
we will now endeavor to design a Code that is action-
able and applicable and practicable for funders, regula-
tors, researchers, clinicians, and patient-participants using 
genomic and clinical data. We will engage stakeholders 
around the world over the coming year to help co-design 
this Code. In the spirit of collaboration, and to honor the 
principle of citizenry, we encourage the journal’s reader-
ship, as well as the broader public, to send us questions and 
comments and work with us on this important policymak-
ing project.
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